Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder
Lecanemab Phase III Readout Next Major Milestone
In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.
The US FDA accepted an application for accelerated approval and set a 6 January action date, giving lecanemab ample time to reach the market ahead of Lilly’s competing anti-amyloid antibody donanemab.